Quale v. Novartis Pharmaceuticals Corporation | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Quale v. Novartis Pharmaceuticals Corporation

Sort by

Viewing results 1‒25 of 64

UK politics
‘Cultural sniffiness’ over profit is hurting NHS drug trials, Labour warns
...This article has been amended to clarify details of the proposed drug trial by the NHS and Novartis...
May 12, 2023
The Big Read
The Biden administration takes on the US drugs industry
...Merck, BMS, J&J, Novartis and some trade groups have launched a legal broadside against them, filing lawsuits in several different courts across the US....
September 18, 2023
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Lex PopuliAdvice & Comment
Healthy return proves worth of Haleon spin-out
...Haleon was a joint venture between GSK and Pfizer that included consumer brands acquired from Novartis....
May 5, 2023
Special ReportInnovative Lawyers: Europe
Legal practitioners’ full breadth of expertise
...In 2020, when pharmaceutical manufacturers Roche and Novartis were fined €444mn for allegedly pushing their jointly marketed eye medicine Lucentis over a cheaper alternative, Thill-Tayara successfully argued...
September 22, 2023
FT Magazine
A controversial biotech and an unlikely anorexia treatment
...Psilocybin was first clinically manufactured in 1959 by Sandoz, now part of Novartis, but the company had never commercialised it....
March 2, 2023
Drug prices
Gene therapies may cure disease but can we afford them?
...Novartis said it did not think the decline in sales was linked to reports of deaths of two children who had taken the drug....
December 15, 2022
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Climate change
Complexity of supply chain emissions forces rivals to work together on net zero
...At Swiss pharmaceutical company Novartis, suppliers — which range from producers of ingredients, materials and finished goods to transport and real estate businesses — generate just over 90 per cent of its...
November 1, 2021
Switzerland
Switzerland plans subsidies to offset G7 corporate tax plan
...In the canton of Basel-Stadt for example, home to 201,000 residents as well as the pharmaceutical companies Roche and Novartis, 20 per cent of government revenues — about CHF600m annually — come from corporation...
June 10, 2021
Legal services
Is ‘general counsel’ still a meaningful job title?
...When Shannon Thyme Klinger left the top legal job at Swiss pharmaceutical group Novartis to join US biotech Moderna this month, she was motivated by a deep sense of purpose — professional and personal....
June 15, 2021
Novartis AG
Novartis reaches $642m settlement with US authorities
...The deal settles civil allegations against its US arm, Novartis Pharmaceuticals Corporation, and is the company’s third big resolution with US authorities in recent months....
July 2, 2020
Companies
Prospering in the pandemic: 2020’s top 100 companies
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
January 1, 2021
Jonathan Guthrie
The fallacy behind the rise of passive fund management
...The Big Three are on course to control 40 per cent of the votes in American corporations in a couple of decades....
January 15, 2020
LexEuropean companies
Novartis: one in the eye Premium content
...Large, venerable corporations can struggle to see what lies ahead for their industry. Consider Novartis....
June 29, 2018
Health
FT Health: Is there a doctor on board?
...The pharmaceuticals industry was a big beneficiary of the president's recent tax changes. Here’s our guide to drug pricing....
July 13, 2018
News in-depthCushman & Wakefield Inc
Cushman v the cleaner: the fight over non-competes
...The lawsuit is a stark example of the use of non-competes by large corporations, even against low-level hourly wage workers....
October 16, 2018
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
News in-depthPharmaceuticals sector
Drugmakers struggle to find immunotherapy combinations for cancer
...As the pace of discoveries has quickened in recent years, it has turned into a kind of rock festival for the pharmaceutical industry....
May 30, 2018
FT and Schroders Business Book of the Year 2023
The Theranos tale exposes the dangers lurking in Silicon Valley
...The company had just completed its first big live demonstration for a pharmaceutical company....
November 14, 2018
Health
FT Health: Stem cells — pushing the boundaries
...China's regulator has approved 60,000 TCM medicines — almost a third of the country's pharmaceuticals market, the world's second largest....
September 8, 2017
News in-depthThe Big Read
Quantum computing: the power to think outside the box
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
September 3, 2018
LexUK companies
AstraZeneca: mystique Premium content
...Alternatively, a positive result might encourage unwanted bids from peers such as Novartis and Pfizer....
July 13, 2017
Corporate culture
Legal profession must break its glass ceiling
...In the Fortune 500 — the largest US industrial corporations, listed by revenue — women make up only a quarter of general counsel....
March 8, 2018
European companies
Nestlé and Novartis rethink role in Turkey ad campaign
...Swiss pharmaceuticals group Novartis also hinted its participation was under review. Joe Jimenez, chief executive, this week told journalists that the campaign’s timing was “probably unfortunate”....
April 27, 2017
FT Magazine
Gene therapy helped these children see. Can it transform medicine?
...The commercial potential — and the undoubtedly high price tag — has encouraged backing from some of the best-known life-sciences investors and Swiss pharmaceutical group Novartis....
October 19, 2017
US & Canadian companies
Investors bet on Incyte cancer drug success
...While Mr Hoppenot shows little interest in selling the company, he has not been averse to signing research deals with larger pharmaceutical groups....
April 19, 2017
FirstFT
Daily briefing: explosions in Texas, new digital currency, whither political Islam?
...(FT, Independent, Bloomberg) Expensive medicine Swiss pharmaceuticals group Novartis has said it would charge $475,000 per patient for its new cancer drug, making the drug one of the most expensive treatments...
August 31, 2017

Previous pagePage 1 of 3Next page